Fingolimod phosphate inhibits astrocyte inflammatory activity in mucolipidosis IV

Area of Science:

• Neuroscience
• Cell Biology
• Genetics

Background:

• Mucolipidosis IV (MLIV) is an orphan neurodevelopmental disease causing severe neurological dysfunction and vision loss.
• MLIV results from loss-of-function mutations in the Mcoln1 gene, encoding the lysosomal channel mucolipin-1 (TRPML1).
• A mouse model with Mcoln1 gene knockout exhibits human-like clinical and neuropathological signs, including astrocyte activation.

Purpose of the Study:

• To investigate the impact of mucolipin-1 loss on astrocyte inflammatory activation in vivo and in vitro.
• To evaluate the therapeutic potential of fingolimod, a clinically approved immunomodulator, in restoring astrocyte homeostasis in Mcoln1-/- mice.

Main Methods:

• Utilized Mcoln1 knockout mice and primary astrocyte cultures to study astrocyte inflammatory responses.
• Analyzed pro-inflammatory cytokine expression and phospho-protein signaling pathways (PI3K/Akt, MAPK).
• Administered fingolimod to Mcoln1-/- mice and cultured astrocytes to assess its effects on cytokine profiles, signaling pathways, and lysosomal compartment.

Main Results:

• Mcoln1-/- mice and astrocytes displayed overexpression of pro-inflammatory cytokines.
• Dysregulated cytokine profiles in Mcoln1-/- astrocytes correlated with altered PI3K/Akt and MAPK signaling.
• Fingolimod treatment normalized cytokine levels, downregulated PI3K/Akt and MAPK signaling, and restored the lysosomal compartment in Mcoln1-/- astrocytes.

Conclusions:

• Loss of mucolipin-1 leads to astrocyte inflammatory activation and signaling pathway dysregulation in MLIV.
• Fingolimod effectively restores astrocyte homeostasis and lysosomal function in the MLIV mouse model.
• Fingolimod represents a promising candidate for preclinical evaluation and potential clinical translation for MLIV treatment.